Dr. Flaherty is director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.

Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1, and PO1 grants. He has been the principal investigator of many clinical trials, including first-in-human trials of novel targeted therapies, and two NCI cooperative group trials. He is a member of numerous scientific cancer societies and national committees, and has authored many research articles, abstracts and reviews in the peer-reviewed literature; including 3 first-author New England Journal of Medicine papers. He serves as a senior editor for Clinical Cancer Research and a member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer, and Pigment Cell and Melanoma Biology.

Dr. Flaherty obtained his undergraduate degree from Yale University in 1993 and an MD from Johns Hopkins University in 1997. He completed his internship in medicine, followed by a residency in medicine, at Brigham and Women’s Hospital (Harvard Medical School) in Boston. He went on to complete a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.

Dr. Flaherty came to Mass General from the University of Pennsylvania Abramson Cancer Center where he was an Assistant Professor of Medicine at the University of Pennsylvania School of Medicine and an Adjunct Professor at the Wistar Institute.